Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Anti-PSMA monoclonal antibody increases the toxicity of paclitaxel carried by carbon nanotubes

Texto completo
Autor(es):
Comparetti, Edson Jose [1] ; Romagnoli, Graziela Gorete [2, 1, 3] ; Gorgulho, Carolina Mendonca [2, 1] ; Pedrosa, Valber de Albuquerque [1] ; Kaneno, Ramon [1]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Sao Paulo State Univ UNESP, Inst Biosci, Dept Chem & Biol Sci, Rua Prof Dr Plinio Pinto e Silva S-N, BR-18618691 Botucatu, SP - Brazil
[2] Sao Paulo State Univ UNESP, Sch Med Botucatu, Dept Pathol, Botucatu, SP - Brazil
[3] UNOESTE Oeste Paulista Univ, Dept Hlth Sci, Jau, SP - Brazil
Número total de Afiliações: 3
Tipo de documento: Artigo Científico
Fonte: Materials Science & Engineering C-Materials for Biological Applications; v. 116, NOV 2020.
Citações Web of Science: 0
Resumo

Multiple-wall carbon nanotubes (CNTs) were functionalized with polyethyleneimine in order to incorporate paclitaxel (PTX), the first line chemotherapeutic agent for prostate cancer. These particles were then covered with antibodies for the prostate-specific membrane antigen (PSMA), to address them to prostate cancer cells. LNCaP prostate cancer cells (PSMA(+)), HCT-116 and CaCo-2 colon cancer cells (PSMA(-)), as well as human peripheral monocytes and lymphocytes (PSMA(-)), were in vitro exposed to fluorescent CNT composites. The interaction/adherence of those composites to target cells was analyzed by fluorescence microscopy and flow cytometry, showing a diffuse interaction of CNTs and CNT-PTX with all cell types. Analysis of cytotoxicity revealed that both prostate (PSMA(+)) and colorectal cancer cells (PSMA(-)) were more susceptible to PTX complexed with CNTs than to pure PTX or CNTs alone, while the incorporation of anti-PSMA (CNT-PTX-PSMA) improved the toxicity on LNCaP cells but not on PSMA- targets. No toxicity was observed in human monocytes and lymphocytes but composites induced phenotypical changes in monocytes. Our results demonstrate the feasibility of using anti-PSMA antibody to address drug-loaded CNT to cancer cells as a strategy for improving the effectiveness of antineoplastic agents. (AU)

Processo FAPESP: 12/20494-5 - Potencial terapêutico antitumoral de células dendríticas sensibilizadas com exossomos alogênicos carregados com peptídeos prostáticos
Beneficiário:Graziela Gorete Romagnoli
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 14/26032-9 - Ação do paclitaxel transportado por nanotubos de carbono sobre células de câncer prostático
Beneficiário:Edson José Comparetti
Linha de fomento: Bolsas no Brasil - Mestrado